Join Precision BioSciences for an investor webcast featuring MF Yuen, MD, PhD (University of Hong Kong, Queen Mary Hospital, Hong Kong), and Mark Sulkowski, MD (Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center), who will join company management to discuss new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial.

The event will review new clinical data along with late-breaker biopsy data featured at the European Association for the Study of the Liver (EASL) Congress 2026 on May 27, 2026, in Barcelona, Spain. The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B.

A live question-and-answer session will follow the formal presentations.